2m 2m 2m 2m 2m 2m 2m
SERINA THERAP (SER)
NYSE
$1.78-$0.01 (-0.61%)
Price as of Jun 03, 2026 7:30 PM EDT- $27.6MMarket Cap
- -70.14%1-Year Change
- BiotechnologyIndustry
SERINA THERAP (SER)
$1.78-$0.01 (-0.61%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 130,000 N/A | 0 -100.00% | 142,000 +317.65% | 34,000 -76.39% | |
Cost of Revenue | N/A N/A | N/A N/A | 40,000 +207.69% | 13,000 -31.58% | |
Gross Profit | 130,000 N/A | 0 -100.00% | 102,000 +385.71% | 21,000 -83.20% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -13.2M +75.87% | -7.5M +919.07% | -734,000 -28.39% | -1.0M -29.60% | |
Depreciation and Amortization Expense | 73,000 -62.37% | 194,000 +48.09% | 131,000 -0.76% | 132,000 +0.76% | |
Total Operating Expenses | 24.2M +41.21% | 17.1M +69.99% | 10.1M +43.83% | 7.0M -14.31% | |
Operating Profit | -24.0M +40.91% | -17.0M +72.43% | -9.9M +41.75% | -7.0M -12.08% | |
Interest Income | N/A N/A | 228,000 +1,972.73% | 11,000 -15.38% | 13,000 N/A | |
Interest Expense | N/A N/A | N/A N/A | -4.9M +46.93% | -3.3M +204.01% | |
Interest Income and Expense and Net | 0 -100.00% | 228,000 +104.66% | -4.9M +47.17% | -3.3M +202.83% | |
Total Nonoperating Income and Expense | 4.8M -17.39% | 5.8M +218.62% | -4.9M +38.82% | -3.5M +446.53% | |
Income before Taxes | -19.2M +12.61% | -17.0M +72.43% | -9.9M -6.03% | -10.5M +21.15% | |
Income Taxes | 18,000 N/A | 0 N/A | N/A N/A | N/A N/A | |
Extraordinary Items | 0 N/A | 0 N/A | N/A N/A | N/A N/A | |
Net Income | -19.2M +72.17% | -11.1M -24.74% | -14.8M +41.49% | -10.5M +20.60% | |
Net Income from Continuing Operations Applicable to Common | -19.4M +74.45% | -11.1M -24.74% | -14.8M +41.49% | -10.5M +21.95% | |
Basic EPS and Net Income | -1.91 +26.49% | -1.51 -88.99% | -13.72 +4,800.00% | -0.28 +21.74% | |
Diluted EPS and Net Income | -1.91 +26.49% | -1.51 -88.99% | -13.72 +4,800.00% | -0.28 +21.74% | |
Basic Weighted Average Shares | 10.2M +38.47% | 7.4M +681,920.39% | 1,079 -100.00% | 37.9M +0.16% | |
Diluted Weighted Average Shares | 10.2M +38.47% | 7.4M +681,920.39% | 1,079 -100.00% | 37.9M +0.16% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 3.1M -16.78% | 3.7M +964.35% | 345,000 -46.51% | 645,000 +10.45% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 3.1M -16.78% | 3.7M +964.35% | 345,000 -46.51% | 645,000 +10.45% | |
Total Current Assets | 6.1M +7.12% | 5.7M +652.79% | 754,000 -69.26% | 2.5M +9.80% | |
Accumulated Depreciation | 528,000 -12.15% | 601,000 N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 465,000 -7.19% | 501,000 N/A | N/A N/A | N/A N/A | |
Total Long-Term Assets | 465,000 -7.19% | 501,000 +100.40% | 250,000 0.00% | 250,000 N/A | |
Total Assets | 7.0M +3.38% | 6.7M -43.80% | 12.0M +269.18% | 3.2M +2.76% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | 14.6M +297.60% | 3.7M -52.84% | 7.8M +9.06% | |
Total Current Liabilities | 3.6M +50.59% | 2.4M -59.99% | 5.9M -41.32% | 10.1M +12.39% | |
Total Long-Term Debt | 2.9M N/A | 0 -100.00% | 693,000 -93.39% | 10.5M +72.85% | |
Total Long-Term Liabilities | 196,000 -94.91% | 3.9M -68.96% | 12.4M +6,790.00% | 180,000 -81.29% | |
Total Liabilities | 7.0M +12.42% | 6.2M -5.92% | 6.6M -67.86% | 20.6M +36.78% | |
Retained Earnings | -63.5M +43.28% | -44.3M -66.17% | -131.0M +12.74% | -116.2M +9.89% | |
Total Stockholders Equity | -37,000 -105.77% | 641,000 -88.28% | 5.5M +131.77% | -17.2M +45.47% | |
Total Shares Outstanding | 10.8M +14.28% | 9.4M +773.22% | 1.1M -97.16% | 37.9M +0.02% | |
Cash Flow | |||||
Cash from Operating Activities | -18.0M +4.77% | -17.1M +119.71% | -7.8M +31.34% | -5.9M -24.39% | |
Capital Expenditures | 59,000 +168.18% | 22,000 N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | -59,000 +168.18% | -22,000 -99.78% | -10.0M N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 17.4M +31.79% | 13.2M -24.50% | 17.5M +191.67% | 6.0M -17.20% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | 71.83% +16.30% | 61.76% -28.85% | |
Operating Margin | -18,478.46% N/A | N/A N/A | -6,962.68% -66.06% | -20,514.71% +272.38% | |
Return on Assets | -280.54% +135.30% | -119.23% -38.76% | -194.70% -40.49% | -327.19% +33.50% | |
Return on Equity | -6,351.66% +1,641.70% | -364.68% -244.65% | 252.12% +249.96% | 72.04% -29.63% | |
Revenue Growth | N/A N/A | -100.00% -131.48% | 317.65% +515.83% | -76.39% -17.23% | |
Current Ratio | 1.71 -28.87% | 2.40 +1,781.57% | 0.13 -47.62% | 0.24 -2.29% | |
Cash Ratio | 0.86 -44.74% | 1.55 +2,562.09% | 0.06 -8.91% | 0.06 -1.69% | |
Debt-to-Equity Ratio | N/A N/A | 22.78 +2,753.89% | 0.80 +175.21% | -1.06 -4.89% | |
Debt-to-Assets Ratio | N/A N/A | 2.17 +495.20% | 0.36 -93.53% | 5.64 +34.64% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow